|
|
|
|
|
Clavulanate
drug data and news
Clavulanate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Clavulanate | ||
| Brand Names/Synonyms | Clavulanate; Clavulanic Acid | ||
| Indication | For use with Amoxicillin, clavulanic acid is suitable for the treatment of infections with Staph. aureus and Bacteroides fragilis, or with beta-lactamase producing H. influenzae and E. coli. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Clavulanic acid, produced by the fermentation of Streptomyces Clavuligerus, is a beta-lactam structurally related to the penicillins. Clavulanic acid is used in conjunction with amoxicillin for the treatment of bronchitis and urinary tract, skin, and soft tissue infections caused by beta-lactamase producing organisms. | ||
| Mechanism Of Action | Clavulanic acid competitively and irreversibly inhibits a wide variety of beta-lactamases, commonly found in microorganisms resistant to penicillins and cephalosporins. By inactivating beta-lactamase (the bacterial resistance protein), the accompanying penicillin/cephalosporin drugs may be made more potent. | ||
| Clavulanate News (When available) |
Orf Virus Infection in Humans—New York, Illinois, California ... Feb 28, 2006 Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006 DSM: Annual Report 2005: Highlights: Life Science Products Feb 10, 2006 GlaxoSmithKline's Topical Antibacterial Retapamulin Accepted for ... Feb 14, 2006 GlaxoSmithKline's Topical Antibacterial Retapamulin Accepted for ... Feb 14, 2006 | ||
| Dosage Forms | Tablets, ER tablets, suspensions | ||
| Drug_Category | Anti-bacterial Agents; ATC:J01C | ||
| Absorption | 75% | ||
| Interactions | The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients. In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR. No rashes were reported in these patients. However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use. In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives | ||
| Toxicity | gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea. Rash, hyperactivity, or drowsiness have also been observed in a small number of patients | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylicacid | ||
| Chemical Formula | C8H9NO5 | ||
| Molecular Weight | 199.161 g/mol | ||
| Smiles String | C1C2N(C1=O)C(C(=CCO)O2)C(=O)O | ||
| Melting Point | 117.5-118 °C | ||
| Water Solubility | 300 mg/mL (potassium salt) | ||
| State | Solid | ||
| LogP/Hphobicity | -0.919 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 1.0 hour | ||
| Protein Binding [%] | Low (22 to 30%) | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | Not Available | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00049 | ||
| CAS Registry Number | 58001-44-8 | ||
| KEGG Compound ID | C06662 | ||
| PubChem ID | SID:8887 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |